News

Health data from more than 50,000 adults revealed racial differences in cardiovascular mortality disappeared after adjusting for social risk factors.

This analysis demonstrated the efficacy of topical azelaic acid, though further randomized control trial evidence may be needed for an evaluation of the treatment on skin aging.

The results of this analysis indicated that while improvement was seen in both groups, slight dermoscopy score improvement was observed in those given a combination laser-minoxidil treatment compared to only minoxidil.

The pioneer in social anxiety disorder discusses his involvement in a promising, fast-acting nasal spray showing promising outcomes in late-stage trials.

Secondary endpoints, including safety, efficacy, immunogenicity, and pharmacokinetics, were highly similar between infliximab and biosimilar CMAB008.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our July 2023 month-in-review features a recap of conference coverage from the ASRS 41st Annual Scientific Meeting.

A new analysis suggests pseudomyopia was an independent risk factor for myopia development among school-aged children in China.

This new research further highlights the importance of addressing traffic pollution as an environmental justice issue, as it impacts pregnancies and leads to disparities in traffic-related exposure levels.

This new data indicates opportunities which may have been missed for initiation of fracture prevention for elderly individuals treated with oral corticosteroids.

In their latest column, Kim Zuber, PA-C, and Jane Davis, DNP, break down the concept of "sick day rules" and what this means for providers caring for those with kidney disease.

This new research indicates a potentially-promising new way of addressing clinical management of prurigo nodularis.

Large learning model-based platforms provide largely inaccurate responses to questions concerning vitreoretinal disease and remain inconsistent on repeat queries.

Pharmacokinetic parameters and bioequivalence were comparable among patients receiving reference tocilizumab and its proposed biosimilar, HS628.

A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.

New study data indicate the growing knowledge of artificial intelligence chatbots in ophthalmology. We are joined by 3 study investigators to discuss what this could mean for the field overall and its impact on patient care.

Data support the benefit of bariatric surgery in patients at high risk of pancreatic ductal adenocarcinoma due to BMI and metabolic comorbidities.

This new data may need to be examined by health providers when they advise patients about treatment outcomes for increasing dosage, including those who could benefit from a higher dose of baricitinib.

In this interview segment, Dr. Lim further discussed findings from his team’s research into infrared radiation’s effects on the skin and the implications of these findings.

In a Q&A, Clipper Young, PharmD, MPH, discusses the Pharm2Home Initiative based on his presentation from ADCES 2023 and describes the impact of community-driven, pharmacist-led interventions to improve health literacy in those with chronic disease.

A single dose of intravitreal bevacizumab in individuals undergoing trabeculectomy for progressing glaucoma shows improved postoperative outcomes at 12 months.

This interview featured a discussion with Dr. Lim on his team’s findings regarding the effects of infrared radiation on human skin.

New 96-week data from PULSAR show patients treated with aflibercept 8 mg achieved good durability and maintained visual acuity gains from year 1 through year 2 of study.

Instances of urgent IBD hospitalization, surgery, death or lack of response to steroid therapy are linked to symptoms of depression and anxiety.

Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.

Investigators find that while general hospitalizations decreased in 2020, hospitalizations due to alcohol-associated hepatitis increased by 16%.

Positive results from REMIX-1 and REMIX-2 on remilbrutinib could mean the beginning of a new class of chronic spontaneous urticaria therapy in about a decade.

Qazi reviews an analysis of an EHR-assisted smoking cessation module that could improve conversations between specialists and patients.

New 12-week data shows an investigative oral drug provided significant benefit in key outcomes associated with NASH disease relief.